ANXA9 and colorectal carcinoma: Our results reveal a mechanism underlying oxaliplatin resistance and suggest that targeting the ZMYM2/ANXA9 axis with G749 may offer a therapeutic strategy to overcome chemotherapy resistance in CRC patients.